Inj., aprepitant, 1 mg
Products billed under this code include Cinvanti.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.Products billed under this code include Cinvanti.
Payment limit per 1 MG, by effective quarter, 1Q21 to 4Q26. Gaps mean the code was not in that quarter’s file, or CMS gave no payment limit.From the 4Q26 NDC–HCPCS crosswalk. “Limit / pkg” is the 4Q26 payment limit times the billing units in one package.
| Product | Labeler | NDC | Units / pkg | Limit / pkg |
|---|---|---|---|---|
| Cinvanti | Heron Therapeutics | 47426-0201-01 | 130 | $211.12 |
| Quarter | Payment limit | Change | Billing unit | Description | Source file |
|---|---|---|---|---|---|
| 4Q26 | $1.624 | +$0.033 | 1 MG | Inj., aprepitant, 1 mg | v1, posted September 17, 2026 |
| 3Q26 | $1.591 | −$0.101 | 1 MG | Inj., aprepitant, 1 mg | v1, posted September 15, 2026 |
| 2Q26 | $1.692 | −$0.021 | 1 MG | Inj., aprepitant, 1 mg | v1, posted September 15, 2026 |
| 1Q26 | $1.713 | +$0.072 | 1 MG | Inj., aprepitant, 1 mg | v1, posted September 15, 2026 |
| 4Q25 | $1.641 | −$0.132 | 1 MG | Inj., aprepitant, 1 mg | v1, posted September 8, 2026 |
| 3Q25 | $1.773 | +$0.063 | 1 MG | Inj., aprepitant, 1 mg | v1, posted March 10, 2026 |
| 2Q25 | $1.71 | +$0.009 | 1 MG | Inj., aprepitant, 1 mg | v1, posted March 10, 2026 |
| 1Q25 | $1.701 | −$0.064 | 1 MG | Inj., aprepitant, 1 mg | v1, posted December 19, 2025 |
| 4Q24 | $1.765 | +$0.049 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 11, 2025 |
| 3Q24 | $1.716 | +$0.05 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 11, 2025 |
| 2Q24 | $1.666 | −$0.063 | 1 MG | Inj., aprepitant, 1 mg | v1, posted March 11, 2025 |
| 1Q24 | $1.729 | −$0.009 | 1 MG | Inj., aprepitant, 1 mg | v1, posted December 19, 2024 |
| 4Q23 | $1.738 | +$0.007 | 1 MG | Inj., aprepitant, 1 mg | v1, posted October 10, 2024 |
| 3Q23 | $1.731 | −$0.074 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 5, 2024 |
| 2Q23 | $1.805 | +$0.076 | 1 MG | Inj., aprepitant, 1 mg | v1, posted February 23, 2024 |
| 1Q23 | $1.729 | +$0.047 | 1 MG | Inj., aprepitant, 1 mg | v1, posted December 6, 2023 |
| 4Q22 | $1.682 | −$0.038 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 22, 2023 |
| 3Q22 | $1.72 | −$0.01 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 9, 2023 |
| 2Q22 | $1.73 | +$0.008 | 1 MG | Inj., aprepitant, 1 mg | v1, posted December 14, 2022 |
| 1Q22 | $1.722 | +$0.031 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 8, 2022 |
| 4Q21 | $1.691 | +$0.079 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 2, 2022 |
| 3Q21 | $1.612 | +$0.164 | 1 MG | Inj., aprepitant, 1 mg | v1, posted June 2, 2022 |
| 2Q21 | $1.448 | −$0.145 | 1 MG | Inj., aprepitant, 1 mg | v1, posted March 1, 2022 |
| 1Q21 | $1.593 | – | 1 MG | Inj., aprepitant, 1 mg | v1, posted December 10, 2021 |
“Change” is the difference from the previous quarter, shown only when both quarters have a payment limit and the billing unit is the same. “vs. last quarter” and “vs. a year ago” follow the same rule.